Table 2.

Summary of clinical trials for cancers with FDA-approved use of ipilimumab.

Trial	Cancer	Treatments	Overall Response Rate (%) 1	Overall Survival Rate (%) 2
NCT00094653 [2]	Unresectable or metastatic melanoma	gp100 (n = 136)	1.5	13.7 (2-yr)
		Ipilimumab (3 mg/kg) (n = 137)	10.9	23.5
		Ipilimumab (3 mg/kg) + gp100 (n = 403)	5.7	21.6
NCT01844505 [114]	Unresectable or metastatic melanoma (BRAF V600—wildtype or mutant)			BRAF-wildtype	BRAF-mutant
		Nivolumab (3 mg/kg) (n-316)	45	22 (6.5-yr)	25 (6.5-yr)
		Ipilimumab (3 mg/kg) (n = 315)	19	42	43
		Ipilimumab (3 mg/kg) + nivolumab (3 mg/kg) (n = 314)	58	46	57
NCT00636168 [3]	Stage III melanoma—adjuvant therapy	Placebo (n = 476)	N/A	54.4 (5-yr)
		Ipilimumab (10 mg/kg) (n = 475)		65.4
NCT02231749 [115]	Advanced renal cell carcinoma	Sunitinib (n = 422)	26.5	60 (1.5-yr)
		Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) (n = 425)	41.6	75
NCT02231749 [116]	MSI-H/dMMR metastatic colorectal cancer	Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) (n = 119)	55	85 (1-yr)
NCT01658878 [117]	Hepatocellular carcinoma	Nivolumab (1 mg/kg) + ipilimumab (3 mg/kg) (n = 50)	32	48 (2-yr)
		Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) (n = 49)	31	30
		Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) (n = 49)	31	42
NCT02477826 [118]	Metastatic NSCLC (≥1% PD-L1)	Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) (n = 396)	35.9	40 (2-yr)
		Platinum-doublet chemotherapy (n = 397)	30	32.8
NCT03215706 [119]	Metastatic or recurrent NSCLC	Nivolumab (360 mg) + ipilimumab (1 mg/kg) + platinum-doublet chemotherapy (n = 361)	38	63 (1-yr)
		Platinum-doublet chemotherapy (n = 358)	25	47
NCT02899299 [120]	Unresectable malignant pleural mesothelioma	Nivolumab (3 mg/kg) + ipilimumab (1 mg/kg) (n = 303)	40	41 (2-yr)
		Platinum + pemetrexed chemotherapy (n = 302)	43	27

¹ Values based on blinded independent central review (BICR) assessment if available. ² Overall survival rate timepoint indicated in brackets.